Max Chat
Calendrier des promotions Alzamend Neuro, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Paramètres de base
IPO date
2021-06-15
ISIN
US02262M3088
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0 | 0 |
| P/BV | -9.27 | 0 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -303.88 | 0 |
| ROE | -4408.31 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0304 | 10 |
| Debt/Ratio | 0.4761 | 10 |
| Debt/Equity | -1.24 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 0 | 0 |
| Rentabilité Ebitda, % | 124.7 | 10 |
| Rentabilité EPS, % | 5901.35 | 10 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 3.24 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 3.34 $ | 0 $ | 0 $ | -2.99 % | 0 % | 0 % |
| common.calendar.number_days.30d | 3.65 $ | 3.19 $ | 3.62 $ | -11.23 % | 0 % | 0 % |
| common.calendar.number_days.90d | 0.767 $ | 0.54 $ | 5.44 $ | 322.43 % | 0 % | 0 % |
| common.calendar.number_days.180d | 1.14 $ | 0.54 $ | 5.44 $ | 184.21 % | 0 % | 0 % |
| common.calendar.number_days.1y | 2.37 $ | 0.54 $ | 5.85 $ | 36.71 % | 0 % | 0 % |
| common.calendar.number_days.3y | 0.971 $ | 0.1722 $ | 29.25 $ | 233.68 % | 0 % | 0 % |
| common.calendar.number_days.5y | 0.1722 $ | 0.1722 $ | 29.25 $ | 1881.53 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.1722 $ | 0.1722 $ | 29.25 $ | 1881.53 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 1.14 $ | 0.54 $ | 5.44 $ | 184.21 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Stephan Jackman | CEO & Director | 434.24k | 1976 (49 années) |
| Mr. David J. Katzoff | Chief Financial Officer | 116.67k | 1962 (63 année) |
| Mr. Henry C. W. Nisser Esq. | Executive VP, General Counsel & Director | 50k | 1969 (56 années) |
| Mr. Milton Charles Ault III | Founder & Vice Chairman | N/A | 1970 (55 années) |
Informations sur l'entreprise
Adresse: United States, Atlanta. GA, 3480 Peachtree Road NE - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.alzamend.com
Site web: https://www.alzamend.com
